['relapsing multiple scelrosis']
['ofatumumab subcutaneous injection', 'teriflunomide-matching placebo capsules', 'teriflunomide capsule', 'matching placebo of ofatumumab subcutaneous injections']

        Inclusion Criteria:

          -  18 to 55 years of age

          -  Diagnosis of multiple sclerosis (MS)

          -  Relapsing MS: relapsing-remitting MS (RRMS) or secondary progressive MS (SPMS)

          -  At least 1 relapse during the previous 1 year or 2 relapses during the previous 2
             years or a positive gadolinium-enhancing MRI scan in previous year

          -  Expanded disability status scale (EDSS) score of 0 to 5.5

        Exclusion Criteria:

          -  Primary progressive MS

          -  Disease duration of more than 10 years in patients with an EDSS score of 2 or less

          -  Patients with an active chronic disease of the immune system other than MS

          -  Patients at risk of developing or having reactivation of hepatitis

          -  Patients with active systemic infections or with neurological findings consistent with
             PML
      